BioMarin Pharmaceutical (NASDAQ:BMRN) Issues FY 2025 Earnings Guidance

BioMarin Pharmaceutical (NASDAQ:BMRN) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 4.200-4.400 for the period, compared to the consensus EPS estimate of 4.160. The company issued revenue guidance of $3.1 billion-$3.2 billion, compared to the consensus revenue estimate of $3.1 billion.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Wedbush raised shares of BioMarin Pharmaceutical to a “strong-buy” rating in a research note on Monday, November 4th. Evercore ISI lowered their target price on shares of BioMarin Pharmaceutical from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 30th. Canaccord Genuity Group lowered their target price on shares of BioMarin Pharmaceutical from $93.00 to $84.00 and set a “hold” rating on the stock in a research note on Wednesday, October 30th. StockNews.com raised shares of BioMarin Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 11th. Finally, UBS Group lifted their price target on BioMarin Pharmaceutical from $104.00 to $106.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Seven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $94.20.

BioMarin Pharmaceutical Trading Up 1.2 %

BMRN traded up $0.75 on Wednesday, hitting $65.61. The company had a trading volume of 1,776,076 shares, compared to its average volume of 1,508,118. The firm has a market cap of $12.50 billion, a P/E ratio of 39.29, a PEG ratio of 0.57 and a beta of 0.28. BioMarin Pharmaceutical has a 1 year low of $60.63 and a 1 year high of $94.85. The company’s fifty day moving average price is $64.79 and its 200 day moving average price is $71.10. The company has a current ratio of 4.27, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, beating the consensus estimate of $0.54 by $0.18. BioMarin Pharmaceutical had a return on equity of 8.53% and a net margin of 11.71%. As a group, equities analysts expect that BioMarin Pharmaceutical will post 2.5 earnings per share for the current year.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.